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Abstract
We performed a multistage genome-wide association study (GWAS) including 7,683 individuals
with pancreatic cancer and 14,397 controls of European descent. Four new loci reached genome-
wide significance: rs6971499 at 7q32.3 (LINC-PINT; per-allele odds ratio [OR] = 0.79; 95%
confidence interval [CI] = 0.74–0.84; P = 3.0×10−12), rs7190458 at 16q23.1 (BCAR1/CTRB1/
CTRB2; OR = 1.46; 95% CI = 1.30–1.65; P = 1.1×10−10), rs9581943 at 13q12.2 (PDX1; OR =
1.15; 95% CI = 1.10–1.20; P = 2.4×10−9), and rs16986825 at 22q12.1 (ZNRF3; OR = 1.18; 95%
CI = 1.12–1.25; P = 1.2×10−8). An independent signal was identified in exon 2 of TERT at the
established region 5p15.33 (rs2736098; OR = 0.80; 95% CI = 0.76–0.85; P = 9.8×10−14). We also
identified a locus at 8q24.21 (rs1561927; P = 1.3×10−7) that approached genome-wide
significance located 455 kb telomeric of PVT1. Our study has identified multiple new
susceptibility alleles for pancreatic cancer worthy of follow-up studies.
Pancreatic cancer is the fourth leading cause of cancer-related death in the United States and
the fifth leading cause in the European Union1,2. Over 80% of patients have incurable
disease at the time of diagnosis, and the majority live for less than 12 months3. Rare,
moderately- to highly-penetrant mutations account for a small fraction of the familial
aggregation of pancreatic cancer4. In two previous GWAS called PanScan I5 and PanScan
II6, we identified common variants at four loci associated with risk of sporadic pancreatic
cancer in European populations. Subsequent GWAS demonstrated five distinct susceptibility
loci among individuals of Chinese descent7 and three suggestive loci among individuals of
Japanese descent8.
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In the current study (designated PanScan III), we performed a multistage GWAS of 7,683
individuals diagnosed with pancreatic cancer and 14,397 control individuals of European
descent (Online Methods, Table 1, Supplementary Table 1 and Supplementary Fig. 1). In
stage 1, we newly genotyped 1,582 cases from 13 prospective cohort studies, 2 case series,
and 1 case-control study using Illumina OmniExpress Beadchip array. The control
population included 5,203 cancer-free individuals previously genotyped using second-
generation Illumina SNP microarrays (e.g. OmniExpress, Omni 1M or Omni 2.5M) and
drawn from PanScan III prospective cohorts and a Spanish case-control study of bladder
cancer. Of newly genotyped cases, 94% passed quality control criteria (Online Methods,
Supplementary Tables 2 and 3), and 712,704 SNPs were included with a minimum call rate
of 94%. In stage 2, we used the primary whole genome scan data from the reported PanScan
I5 (1,757 cases and 1,801 controls from 12 cohort studies and 1 case-control study typed on
Illumina HumanHap550 array) and PanScan II6 (1,768 cases and 1,841 controls from 8 case-
control studies typed with Illumina Human 610-Quad array) studies. To address differences
in typed SNPs across the arrays, we utilized the DCEG Imputation Reference Set9 to fill in
missing genotypes (Online Methods).
In a meta-analysis of stages 1 and 2, we observed robust associations for the four previously
identified loci in individuals of European descent: rs687289 at 9q34.2 (ABO, OR = 1.27;
95% CI = 1.20–1.35; P = 1.6×10−16), rs9543325 at 13q22.1 (KLF5/KLF12, OR = 1.23; 95%
CI = 1.18–1.30; P = 4.3×10−14), rs10919791 at 1q32.1 (NR5A2, OR = 0.79; 95% CI = 0.75–
0.85; P = 1.4×10−11), and rs31490 at 5p15.33 (CLPTM1L, OR = 1.20; 95% CI = 1.14–1.27
P = 2.0×10−11).
We observed two new SNPs below genome-wide significance (P<5×10−8) in the meta-
analysis of stages 1 and 2, plus 11 additional promising SNPs (P<5×10−5) from distinct
regions (Supplementary Table 4). These 13 SNPs were carried forward for replication (stage
3) in 2,576 cases and 5,552 controls, drawn from: (a) cases in stage 1 with DNA quantity
insufficient for full GWAS, (b) cases and controls from the PANDoRA consortium10, and
(c) cases enrolled to CALGB 80303, a U.S. cooperative group clinical trial11
(Supplementary Table 5). Additional control subjects were selected from cancer-free
individuals previously genotyped using Illumina HumanHap550 array (Online Methods). Of
13 SNPs advanced to replication, nine SNPs were associated with pancreatic cancer risk (P
<0.05) in the replication stage (Supplementary Table 6).
For the complete study of 7,683 cases and 14,397 controls, we applied a fixed-effect meta-
analysis to the results from the three stages. Overall, six SNPs had P-values below genome-
wide significance: rs2736098 at 5p15.33 (a second signal in TERT, P=9.8×10−14),
rs6971499 at 7q32.3 (LINC-PINT, P=3.0×10−12), rs7190458 at 16q23.1 (BCAR1/CTRB1/
CTRB2, P=1.1×10−10), rs9581943 at 13q12.2 (PDX1, P=2.4×10−9), rs16986825 at 22q12.1
(ZNRF3, P=1.2×10−8) (Table 2 and Figure 1), and rs4962153 at 9q34.2 (ADAMTS13,
P=1.5×10−8). In a subsequent conditional analysis described below, rs4962153 in
ADAMTS13 marked the same signal as rs687289 in ABO identified in PanScan I and II. An
additional locus at 8q24.21 was close to genome-wide significance (rs1561927,
P=1.3×10−7) and located in a region previously associated with multiple cancers (Table 2
and Figure 1).
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The SNP, rs6971499, at 7q32.3 maps to an intron in LINC-PINT, which is a p53-induced
long intergenic non-protein coding RNA located in a 375 kb region between Muskelin 1
(MKLN1) and KLF14 (Supplementary Table 7 and Figure 1). Muskelin is an intracellular
protein that mediates cell response to the extracellular matrix, particularly influencing cell
adhesion and cytoskeleton organization12. KLF14 is a member of the Kruppel-like family of
transcription factors, which have been implicated as tumor suppressors, including in mutant
KRAS-driven tumors13. KLF14 has also been identified as a regulator of several metabolic
phenotypes, including type 2 diabetes14. Notably, the previously established susceptibility
locus at 13q22.1 is located in an intergenic region between KLF5 and KLF12, two other
members of the Kruppel-like family of transcription factors.
The SNP, rs7190458, at 16q23.1 is a synonymous SNP residing in the last exon of BCAR1
(also known as p130Cas) and close to two chymotrypsinogen genes, CTRB1 (5 kb) and
CTRB2 (23kb) (Supplementary Table 7 and Figure 1). Aberrant expression of BCAR1 has
been linked with transformation and progression of multiple cancer types, and BCAR1
functions as an adaptor protein that coordinates cell cycle control, cytoskeleton organization,
and cell migration15,16. The chymotrypsinogens are members of a family of serine proteases
that are secreted by the pancreas into the gastrointestinal tract17. Mutations in the related
genes PRSS1 (trypsin 1) and CTRC have been associated with hereditary pancreatitis18, a
known risk factor for pancreatic cancer19. In addition, a susceptibility locus for types 1 and
2 diabetes20,21 is located 16 kb centromeric to rs7190458 (rs7202877, r2=0.32 in 1000G
CEU data). Functional analyses indicate that this variant (rs7202877) leads to impaired
pancreatic beta-cell function22 and influences expression of CTRB1 and CTRB2 in
pancreatic tissue23.
At chromosome 13q12.2, the newly identified SNP, rs9581943, is approximately 200bp
upstream of PDX1 (pancreatic and duodenal homeobox1 protein 1) and intronic to PDX1-
AS1 (PDX1 antisense RNA 1), a recently identified noncoding RNA (Supplementary Table 7
and Figure 1). PDX1 is critical for early pancreatic development, plays a role in
differentiation of exocrine pancreas, and regulates beta-cell function in the mature
pancreas24,25. Mutations in PDX1 have been linked to agenesis of the pancreas24 and
maturity onset diabetes of the young (MODY)26, a dominantly inherited disorder of non-
autoimmune diabetes. Furthermore, PDX1 has been implicated in glucose-dependent
regulation of insulin gene transcription27, and GWAS have identified a SNP (rs2293941,
r2=0.20 in 1000G CEU data) at the PDX1 locus associated with fasting glucose levels28.
The signal at 22q12.1, rs16986825, maps to an intron in ZNRF3 (zinc and ring finger 3)
(Supplementary Table 7 and Figure 1), encoding a cell surface transmembrane E3 ubiquitin
protein ligase that is a negative regulator of the Wnt signaling pathway29. Additionally,
CHEK2 is located 162 kb centromeric to the marker SNP and encodes a cell-cycle
checkpoint kinase that cooperates with p53, BRCA1 and ATM in response to DNA
damage30. Alterations in CHEK2 have been implicated in susceptibility to several cancer
types31.
We performed conditional analyses to assess whether the newly identified SNPs at 5p15.33
(CLPTM1L/TERT) and 9q34.2 (ABO/ADAMTS13) were independent from those identified
Wolpin et al. Page 3
Nat Genet. Author manuscript; available in PMC 2015 March 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
previously. After conditioning on the reported SNP within intron 13 of CLPTM1L, the
newly identified synonymous SNP within the second exon of TERT (rs2736098) remained
statistically significant (P=2.4×10−3) (Table 3). Two strong recombination hotspots lie
between the established and new SNPs in 1000G CEU data (likelihood ratios, LR of 27.1
and 261.0)32, and the two SNPs are in modest linkage disequilibrium (LD; r2=0.22 in 1000G
CEU data) (Figure 1).
TERT encodes the catalytic subunit of telomerase reverse transcriptase, a component of the
ribonucleoprotein complex that maintains integrity of chromosome ends. Inherited
mutations affecting TERT underlie cases of dyskeratosis congenita, aplastic anemia, acute
myeloid leukemia, familial melanoma, and pulmonary fibrosis33,34. CLPTM1L encodes the
cleft lip and palate associated transmembrane 1 like protein involved in mediating apoptosis,
aneuploidy, cisplatin resistance, and RAS-mediated malignant transformation35,36. Variants
across the TERT/CLPTM1L region have previously been associated with risk of multiple
cancers. Furthermore, independent signals within TERT and CLPTM1L have been identified
for bladder cancer37, CLL38, and lung cancer37,39, and fine-mapping studies have identified
at least four independent signals across the TERT/CLPTM1L region associated with
cancer40,41. The new SNP identified in PanScan III (rs2736098) is located in a region of LD
spanning ~4kb from the promoter region to exon 2 of TERT. This SNP and several
correlated SNPs have been associated with telomere length in white blood cells and TERT
promoter activity37,40,41. The minor allele of rs2736098 that is associated with a lower risk
of pancreatic cancer in PanScan was associated with longer telomeres and lower risk of
breast cancer40. Although further characterization of this region will be necessary, the new
SNP in exon 2 of TERT appears to mark an independent risk locus for pancreatic cancer.
After conditioning on the established SNP at 9q34.2 in the first intron of ABO, the SNP
rs4962153 in ADAMTS13 identified in PanScan III was not statistically significant (P=0.28),
indicating that these two SNPs point to the same susceptibility haplotype (Table 3).
A promising risk locus was identified at 8q24.21 (rs1561927; P = 1.3×10−7) in a nongenic
region between PVT1 and LINC00977 (Supplementary Table 7 and Figure 1). 8q24.21 is
known to contain multiple cancer susceptibility loci that span over 2Mb42,43. The promising
pancreatic cancer SNP is in LD with a SNP associated with ovarian cancer risk (rs10088218,
r2=0.37 in 1000G CEU data, 24kb upstream)44, and the closest genes are centromeric to
rs1561927: MIR1208 (406 kb), PVT1 (455 kb), and MYC (814 kb). Several 8q24.21 risk loci
have been shown to interact with MYC or PVT1 promoters through long range chromosomal
interaction, and allele-specific effects on the expression of both genes have been
reported42,45,46. However, these loci are located more than 1 Mb upstream of rs1561927 on
8q24.21 (r2<0.03 in 1000G CEU data).
In stratified analyses, no statistically significant heterogeneity was noted by geographic
region or smoking status (Supplementary Tables 8 and 9). In a preliminary analysis that
included 173 cases and 430 controls of Asian ancestry (Supplementary Table 10), we
examined the susceptibility loci identified in individuals of European descent5,6 (Table 2).
We also assessed previously published pancreatic cancer risk loci from individuals of
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Chinese7 and Japanese8 ancestry, noting no loci and one locus, respectively, as nominally
statistically significant in PanScan (Supplementary Table 11).
To pursue the first steps towards understanding the functional underpinnings of the newly
identified risk alleles, we conducted bioinformatic analyses using HaploReg47
(Supplementary Table 12). We also evaluated expression quantitative trait locus (eQTL)
effects48–50 (Supplementary Table 12). Cis-eQTLs were noted on chr16q23.1 in peripheral
blood (CFDP1), chr13q12.2 in skin and liver (POMP), chr22q12.1 in liver and peripheral
blood (CCDC117) and peripheral blood (XBP1), and chr8q24.21 in adipose tissue (PVT1).
XBP1 at chr22q12.1 regulates pancreatic beta-cell function with effects on systemic glucose
control51 and modulates acinar cell homeostasis25. In gene set enrichment analysis52 of
genes within 100 kb of the 10 index SNPs identified in PanScan, the only statistically
significant pathway was maturity onset diabetes of the young (P=3.3×10−4). Understanding
the functional consequences of pancreatic cancer susceptibility variants will require further
laboratory investigation.
In a linear-mixed model analysis53 (Online Methods), we estimated that the heritability for
pancreatic cancer due to common SNPs present on GWAS arrays was 13% (95% CI, 4–
22%). Furthermore, we estimated that the nine loci identified in individuals of European
ancestry account for approximately 9% of total heritability tagged by common SNPs. We
also evaluated the cumulative association with pancreatic cancer of risk alleles at
susceptibility loci identified in individuals of European descent. Compared to individuals
with the most prevalent number of risk alleles in controls (n=10), those with ≤6 risk alleles
had an OR of 0.55 (95% CI, 0.44–0.68) and those with ≥14 risk alleles had an OR of 2.24
(95% CI, 1.80–2.80) for pancreatic cancer (Supplementary Figure 2).
In conclusion, our multistage GWAS revealed new loci associated with pancreatic cancer
risk, as well as promising loci that merit follow-up. Several of the new loci harbor plausible
candidate genes implicated in pancreas development, pancreatic beta-cell function, and
predisposition to diabetes. Further investigation is warranted to understand the biological
underpinnings of these common pancreatic cancer susceptibility alleles.
ONLINE METHODS
Stage 1: GWAS for PanScan III
We conducted a GWAS of pancreatic cancer using case and control subjects from 17 studies
(Supplementary Table 1). Pancreatic cancer cases included individuals newly identified
from nine cohort studies that participated in PanScan I5, as well as those from five new
cohort studies, two new case series, and one new case-control study. The new cohort studies
included the Agricultural Health Study (AHS)54, Melbourne Collaborative Cohort Study
(MCCS)55, Multiethnic Cohort Study (MEC)56, Selenium and Vitamin E Cancer Prevention
Trial (SELECT)57, and Vitamins and Lifestyle Study (VITAL)58. The new case-based
studies were the Gastrointestinal Cancer Clinic of Dana-Farber Cancer Institute (DFCI-
GCC), Spanish Pancreatic Cancer Study PANKRAS-II59, and PANDoRA-Heidelberg
pancreatic cancer case-control study10. Cases were defined as those individuals having
primary adenocarcinoma of the exocrine pancreas (ICD-O-3 code C250–C259). Those with
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non-exocrine pancreatic tumors (histology types 8150, 8151, 8153, 8155 and 8240) were
excluded. Each participating study obtained informed consent from study participants,
approval from its institutional review board (IRB) for this study, and IRB certification
permitting data sharing in accordance with the NIH Policy for Sharing of Data Obtained in
NIH-Supported or NIH-Conducted Genome-Wide Association Studies.
All samples from pancreatic cancer cases with sufficient DNA (n=1,894) were genotyped on
the Illumina OmniExpress chip at the NCI Cancer Genomic Research Laboratory (CGR)
(Supplementary Table 2). Genotypes were called using the Illumina GenomeStudio
software. Genotype clusters for new cases were estimated using samples with a completion
rate of 98% to optimize accuracy. Genotypes for all samples, including those initially
excluded, were subsequently called based on the optimized cluster file. Extensive quality-
control metrics were applied to the data: SNPs with a call rate <94% or Hardy-Weinberg
Proportion p value <1×10−7 were excluded (n=18,765); samples with a call rate <94%
(n=78), mean heterozygosity <26% or >33% (n=2) based on autosomal SNPs or gender
discordance (>5% heterozygosity based on the X chromosome SNPs for males or <20%
heterozygosity based on the X chromosome SNPs for females, n=5) were excluded.
Unexpected duplicates (>99.9% concordance, n=3) and first-degree relatives (n=2, on the
basis of identity-by-descent sharing with Pi-hat >0.40) were removed. Quality-control
duplicate samples in PanScan III (n=38 pairs) showed >99.9% genotype concordance.
Duplicates with PanScan I or II were removed (>99.9% concordance, n=21). Ancestry was
assessed using the Genotyping Library and Utilities (GLU) struct.admix module.
Participants with <80% European ancestry (n=199) were excluded for the primary analysis
of individuals of European ancestry (Supplementary Fig. 3). After exclusions, 1,582 cases of
European ancestry were available for analysis (Supplementary Tables 2 and 3).
Controls of ≥80% European ancestry were drawn from ten of the studies included in
PanScan III (Alpha-Tocopherol, Beta-Carotene Lung Cancer Prevention Study (ATBC),
American Cancer Society Cancer Prevention Study-II Cohort (CPS-II), European
Prospective Investigation into Cancer and Nutrition (EPIC), Health Professionals Follow-Up
Study (HPFS), Melbourne Collaborative Cohort Study (MCCS), Multiethnic Cohort Study
(MEC), Nurses' Health Study (NHS), Prostate, Lung, Colorectal and Ovarian Cancer
Screening Trial (PLCO), Spanish Pancreatic Cancer Study (SPCS, PANKRAS-II and
Spanish Bladder Cancer SBC/EPICURO studies)60 and Women's Health Initiative (WHI)).
These controls had no history of cancer, were not included in PanScan I or PanScan II, and
had been previously genotyped at CGR on the Illumina OmniExpress, Omni1M or
Omni2.5M arrays, with extensive quality-control as previously described9,61–64. In total,
5,203 controls were included in the analysis (Supplementary Tables 2 and 3). A total of
608,202 SNPs with overall completion rate >80% in both cases and controls were advanced
to the association analysis. To evaluate population substructure, a principal components
analysis was performed using the struct.pca module of GLU, version 1.0, which is similar to
EIGENSTRAT65. Plots of the first six principal components are shown in Supplementary
Figure 4. The estimated inflation of the test statistic, λ, was 1.0266; a Quantile-quantile (QQ)
plot is shown in Supplementary Figure 5.
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Association analysis was performed assuming a log-additive genetic model and adjusting for
age, sex, geographic region and 6 significant eigenvectors (i.e. EVs that were nominally
significant in a baseline risk model adjusting for age, sex, and geographic region).
Geographic region was defined as REGION_US (United States): AgHealth, CPS-II, DFCI,
HPFS, MEC, NHS, NYU-WHS, PHS, PLCO, SELECT, VITAL, WHI; REGION_CNE
(Central and Northern Europe): ATBC, EPIC, PANDoRA-Heidelberg, MCCS (Melbourne);
and REGION_SE (Southern Europe): SBCS (Spain controls), PANKRAS-II (cases). All
data analyses and management were conducted using GLU.
Stage 2: PanScan I and II data
The second stage involved the primary whole genome scan data from the previously
reported PanScan I5 and PanScan II6 studies. PanScan I and PanScan II were genotyped on
the Illumina HumanHap550 Infinium II and the Human 610-Quad chips, respectively,
whereas PanScan III was genotyped on the OmniExpress chip. As the number of
overlapping SNPs between the three chips is moderate (~300K), imputation of missing
genotypes was performed using phased haplotypes from the DCEG Reference Set and
IMPUTE29,67. The DCEG reference set is well-designed for “filling in” missing genotypes
across chip designs in PanScan since it is based on several of the same studies included in
PanScan and the imputation accuracy is improved over 1,000 Genomes and HapMap data9.
Imputed SNPs with low minor allele frequencies (MAF <0.01) or low-quality scores
(IMPUTE2 information score <0.3) were removed prior to association analysis. The same
quality thresholds as described above for stage 1 were applied for stage 2. Final numbers of
cases and controls included in stage 2 were 1,757 cases and 1,801 controls from PanScan I
and 1,768 cases and 1,841 controls from PanScan II.
To combine data from PanScan I, II, and III, meta-analyses were performed using the fixed-
effects inverse-variance method based on the β estimates and standard errors. No
heterogeneity was observed across stages 1 and 2 for the SNPs identified as GWAS
significant or suggestive in the full study (P heterogeneity ≥0.11; Supplementary Table 4).
Manhattan plot for the results of the meta-analysis of stage 1 and stage 2 is shown in
Supplementary Figure 6.
Association analysis was also performed in 173 cases and 430 controls of Asian ancestry
from the Shanghai Men’s and Women’s Health Study (SMWHS) (Supplementary Table 10).
This analysis included case and control subjects from stages 1 and 2 of PanScan III and
previously genotyped control subjects from SMWHS68. Quality control and association
analysis were performed as described above for European ancestry subjects.
Stage 3: Replication studies
Thirteen SNPs (P-value threshold of <5×10−5) were taken forward for de novo replication in
an additional 2,576 cases and 5,552 controls. The replication samples were analyzed
individually as three groups: (A) CGR: pancreatic cancer case and control subjects from
CARET69 plus samples from cases that did not have sufficient DNA for full GWAS and
control subjects previously genotyped at CGR; (B) PANDoRA: case and control subjects
from the PANDoRA pancreatic cancer case-control consortium10 (no overlap with the
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PANDoRA-Heidelberg cases genotyped in stage 1); and (C) CALBG/Alliance 80303: cases
from a randomized clinical trial of gemcitabine plus placebo versus gemcitabine plus
bevacizumab11, and control subjects previously genotyped at CGR (Supplementary Table
5).
Genotyping for cases in group A was performed using custom TaqMan genotyping assays
(Applied Biosystems) at CGR. Genotyping for cases and controls from PANDoRA (group
B) was performed in the same manner but at the German Cancer Research Center (DKFZ) in
Heidelberg, Germany. Quality-control duplicate samples in the replication (CGR, n=20
pairs; PANDoRA, n=512 pairs) showed >99.9% genotype concordance. Patients enrolled on
CALGB/Alliance 80303 (group C) were previously genotyped using the Illumina
HumanHap550v3 Genotyping BeadChip array11. Control subjects from PLCO previously
genotyped at CGR using the Illumina HumanHap550v3 Genotyping BeadChip array70 were
used for groups (A) and (C) (Supplementary Table 5), and did not overlap with control
subjects included in PanScan I, II or III. CALBG/Alliance 80303 and control genotypes
were imputed to OmniExpress SNP content in the same manner as described above for stage
1. Quality control thresholds and exclusions for sample and loci in the replication are listed
in Supplementary Table 5B. Association results for the replication studies were adjusted for
age, sex and study, and a meta-analysis of the three replication groups was performed using
the fixed-effects inverse-variance method based on the β estimates and standard errors
(Supplementary Table 6). This was followed by a meta-analysis of stages 1, 2 and
replication for the 13 SNPs using the same fixed-effects inverse-variance method.
Technical validation
A comparison of the genotyping calls from the imputation of PanScan I and II into
OmniExpress array contents and confirmatory TaqMan assays (n= 511 samples from
PanScan I and II) yielded an r2 of 0.74, 0.96, 0.56, 0.99, 0.98 and 1.00 for rs2736098,
rs6971499, rs7190458, rs9581943, rs16986825 and rs1561927, respectively.
Estimate of recombination hotspots
To identify recombination hotspots, we used SequenceLDhot32, a program that uses the
approximate marginal likelihood method71 and calculates likelihood-ratio statistics at a set
of possible hotspots. We tested five unique sets of 100 control samples. The PHASE v2.1
program was used to calculate background recombination rates72,73, and LD heat maps were
visualized using the snp.plotter program74. For estimation of recombination hotspots
between loci in TERT and CLPTM1L on chr5p15.33, we used the 1000G (version 3) CEU
data.
Heritability analysis
To estimate heritability explained by common SNPs present on GWAS arrays on the
liability scale (lifetime disease risk of 0.015), we used GCTA53,75 on a set of LD-pruned
SNPs (r2<0.5) that passed the following stringent quality control thresholds: MAF>1%, SNP
missing rates <5%, subject missing rate <1%, and HWE P-values >10−4. Non-autosomal
SNPs and pairs of subjects with genetic relatedness >5% were removed. These analyses
were run separately in PanScan I, II and III, adjusting for age, sex, study (or geographic
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region in PanScan III) and the significant principal components in each study. PanScan III
analyses were restricted to participating studies that contributed both cases and controls.
PanScan I, II, and III results were combined via meta-analysis. We repeated the analyses
restricted to the genome-wide significant SNPs in individuals of European ancestry to
estimate the proportion of heritability tagged by these nine SNPs.
Further follow-up analyses
We constructed a genetic risk score for pancreatic cancer, incorporating the susceptibility
loci identified in PanScan I, II, and III. For this analysis, subjects could possess zero to 20
risk alleles, based on their genotypes at the 10 identified loci. Odds ratios were calculated
using multivariable-adjusted unconditional logistic regression with meta-analysis to
combine data from stages 1 and 2, as done in the analyses of individual SNPs. Replication
samples were not genotyped for the four susceptibility loci identified in PanScan I and II,
and therefore, these subjects could not be included in the risk score analysis. Subjects with
missing genotypes for one or more of the 10 SNPs (n=898) were assigned the most common
genotype at that SNP among cases or controls. In sensitivity analyses, results were
unchanged if these subjects were excluded. Using 1000 Genomes CEU data, we identified
SNPs with r2 >0.7 with our lead SNP. We used HaploReg v247, a tool for exploring
noncoding functional annotation using ENCODE data, to evaluate the genome surrounding
our SNPs (Supplementary Table 12). In addition, we evaluated cis associations between all
new and promising SNPs discovered in this study and the expression of nearby genes in skin
biopsies, adipose biopsies and non-transformed peripheral blood samples from subjects of
European descent from publically available data sets48,50 (Supplementary Table 12). Gene
set enrichment analysis was also performed for genes in pancreatic cancer risk loci identified
in subjects of European descent (in a window of 100 kb centered on the most significant
SNP in each locus) based on KEGG (Kyoto Encyclopedia of Genes and Genomes)
annotations using GeneCodis3 with reporting of the corrected hypergeometric P-value52.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Association results, recombination hotspots and LD plots for new pancreatic cancer
susceptibility regions (a–e) and one suggestive region (f)
Top, association results of GWAS data from the stage 1 (gray diamonds), stage 2 (purple
diamonds), replication (blue diamonds) and the combined data from stages 1–3 (red
diamonds) plotted against −log10 P values (left y axis). Overlaid are likelihood ratio
statistics (right y axis) estimating putative recombination hotspots across the region on the
basis of five unique sets of 100 randomly selected control samples. Bottom, LD heat map
based on r2 values from the total control populations for all SNPs included in the GWAS.
The data are based on a total number of 7,683 individuals with pancreatic cancer and 14,397
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controls of European descent. Shown are results for 5p15.33 (a), 7q32.3 (b), 16q23.1 (c),
13q12.2 (d), 22q12.1 (e), and 8q24.1 (f).
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Table 1
Subject numbers and characteristics of pancreatic cancer cases and controls
Cases
No. (%)
Controls
No. (%)
No. of subjects
  Stage 1 1,582 5,203
  Stage 2 3,525 3,642
  Replication 2,576 5,552
  Full study population 7,683 14,397
Geographic region
  United States 4,387 (57.1) 7,962 (55.3)
  Central/Northern Europe 2,264 (29.5) 3,853 (26.8)
  Southern Europe 1,032 (13.4) 2,582 (17.9)
Sex
  Male 4,107 (53.5) 8,841 (61.4)
  Female 3,576 (46.5) 5,556 (38.6)
Age, years
  ≤ 60 1,972 (25.7) 4,577 (31.8)
  61 – 70 2,688 (35.0) 5,906 (41.0)
  > 70 3,023 (39.3) 3,914 (27.2)
Smoking status*
  Current / past 2,634 (51.6) 4,541 (51.3)
  Never 1,642 (32.2) 3,186 (36.0)
  Unknown 831 (16.3) 1,118 (12.6)
*Smoking status was available for subjects in Stages 1 and 2.
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